These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 21085915

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [Abstract] [Full Text] [Related]

  • 5. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF.
    Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
    [Abstract] [Full Text] [Related]

  • 6. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J, Leung B, Poole P.
    Cochrane Database Syst Rev; 2017 Sep 19; 9(9):CD002309. PubMed ID: 28922692
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA.
    Int J Chron Obstruct Pulmon Dis; 2011 Sep 19; 6():147-55. PubMed ID: 21468165
    [Abstract] [Full Text] [Related]

  • 13. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF.
    Br J Pharmacol; 2011 May 19; 163(1):53-67. PubMed ID: 21232047
    [Abstract] [Full Text] [Related]

  • 14. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
    Cazzola M, Picciolo S, Matera MG.
    Expert Opin Pharmacother; 2010 Feb 19; 11(3):441-9. PubMed ID: 20102307
    [Abstract] [Full Text] [Related]

  • 15. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA, Hamilton LA, Hughes A.
    Clin Ther; 2012 Jan 19; 34(1):56-66. PubMed ID: 22284994
    [Abstract] [Full Text] [Related]

  • 16. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
    Giembycz MA, Field SK.
    Drug Des Devel Ther; 2010 Jul 21; 4():147-58. PubMed ID: 20689641
    [Abstract] [Full Text] [Related]

  • 17. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML.
    Consult Pharm; 2012 Mar 21; 27(3):189-93. PubMed ID: 22421519
    [Abstract] [Full Text] [Related]

  • 18. Roflumilast for asthma and chronic obstructive pulmonary disease.
    Cowan C.
    Issues Emerg Health Technol; 2005 Oct 21; (74):1-4. PubMed ID: 16317827
    [Abstract] [Full Text] [Related]

  • 19. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
    Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA.
    Swiss Med Wkly; 2012 Oct 21; 142():w13628. PubMed ID: 22833385
    [Abstract] [Full Text] [Related]

  • 20. [Clinical profile of roflumilast].
    Izquierdo Alonso JL.
    Arch Bronconeumol; 2010 Dec 21; 46 Suppl 10():25-32. PubMed ID: 21316553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.